CAGE Bio Announces Positive Clinical Phase 2 Study Results for Atopic Dermatitis

  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us
  • More
    • Home
    • About Us
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisors
      • Partnerships
    • Our Technology
    • People
      • Our Team
      • Career
    • Patients
      • Clinical Trials
    • Media
      • Press Releases
      • In the news
      • Publications
    • Contact Us
  • Home
  • About Us
    • Board of Directors
    • Scientific Advisory Board
    • Business Advisors
    • Partnerships
  • Our Technology
  • People
    • Our Team
    • Career
  • Patients
    • Clinical Trials
  • Media
    • Press Releases
    • In the news
    • Publications
  • Contact Us

Press Releases

August 03, 2023

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic

San Carlos, CA; Fort Worth, TX

Event Details

August 03, 2023

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic

https://www.accesswire.com/772102/CAGE-Bio-Announces-Positive-Topline-Results-From-its-Double-Blind-Phase-2-Study-Evaluating-an-Ionic-Liquid...

Event Details

San Carlos, CA; Fort Worth, TX

SEPTEMBER 15, 2022

CAGE Bio, TAGCyx, and PeptiStar Announce License Agreement for Dev & Comm. of TAGX-0003

San Carlos, CA; Fort Worth, TX

Event Details

SEPTEMBER 15, 2022

CAGE Bio, TAGCyx, and PeptiStar Announce License Agreement for Dev & Comm. of TAGX-0003

CAGE Bio Inc., announced the execution of a license agreement for development of TAGX-0003 for the targeted treatment of alopecia areata and...

Event Details

San Carlos, CA; Fort Worth, TX

May 11, 2021

CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea

San Carlos, CA; Fort Worth, TX

Event Details

May 11, 2021

CAGE Bio Initiates Phase 2 Study for Treatment of Rosacea

CAGE Bio Inc., announced dosing of the first patient in its Phase 2 clinical trial for the treatment of inflammatory lesions of rosacea. The...

Event Details

San Carlos, CA; Fort Worth, TX

February 16, 2021

CAGE Bio Closes $7.2 Million Round of Series A Funding

San Carlos, CA; Fort Worth, TX

Event Details

February 16, 2021

CAGE Bio Closes $7.2 Million Round of Series A Funding

CAGE Bio Inc., announced the closing of a $7.2 million over-subscribed Series A financing.  The investment was led by professional and angel...

Event Details

San Carlos, CA; Fort Worth, TX

September 18, 2020

TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases

San Carlos, CA; Fort Worth, TX

Event Details

September 18, 2020

TAGCyx announces a research collaboration with CAGE Bio Inc. for autoimmune skin diseases

  1. TAGCyx biotechnologies Inc. announced entering into a research collaboration with CAGE Bio Inc. for development of TAGX-0003 for treatment o...

Event Details

San Carlos, CA; Fort Worth, TX

More Events

Copyright © 2020 CAGE Bio Inc. - All Rights Reserved.

This website uses cookies.

We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.

Accept

Welcome! Check out our latest news.

CAGE Bio Announces Positive Topline Results From its Double-Blind Phase 2 Study Evaluating an Ionic Liquid formulation of 1% Tofacitinib In Patients with Atopic Dermatitis

Learn more